At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiplatelets; Small molecules; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 22 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline